Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

45.9K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
45.9K
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

3.5K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.5K
Drug Therapy01:28

Drug Therapy

43
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
43
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

4.0K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
4.0K
Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response01:15

Chronopharmacokinetics: Circadian Rhythms and Influence on Drug Response

61
Circadian rhythms are cyclic changes that are crucial in plasma drug concentrations. Various standard circadian parameters, including core body temperature, heart rate, and other cardiovascular factors, directly impact disease states and the therapeutic response to drug therapy.
The time of drug administration is an important factor to consider, as it can influence the toxic dose of a drug. For example, a study conducted by Prins et al. in 1997 examined the effects of the timing of...
61
Pharmacovigilance01:19

Pharmacovigilance

830
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
830

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The multifaceted antiretroviral coverage provided by BIC/FTC/TAF: a pharmacokinetic/pharmacodynamic revisitation.

Le infezioni in medicina·2026
Same author

The cerebrospinal fluid virome in people with HIV: links to neuroinflammation and cognition.

Frontiers in microbiology·2025
Same author

Extending follow-up visits in people with HIV (PWH) receiving bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) therapy: an expert opinion.

Le infezioni in medicina·2025
Same author

The cerebrospinal fluid virome in people with HIV: links to neuroinflammation and cognition.

bioRxiv : the preprint server for biology·2025
Same author

How Antiretroviral Drug Concentrations Could Be Affected by Oxidative Stress, Physical Capacities and Genetics: A Focus on Dolutegravir Treated Male PLWH.

Antioxidants (Basel, Switzerland)·2025
Same author

Effectiveness, safety, and patient-reported outcomes of bictegravir/emtricitabine/tenofovir alafenamide in routine clinical care in Italy: 12-Month results from the BICSTaR cohort.

International journal of STD & AIDS·2025

Related Experiment Video

Updated: Jun 28, 2025

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

17.8K

Ritonavir: 25 Years' Experience of Concomitant Medication Management. A Narrative Review.

Romina Quercia1, Giovanni Di Perri2, Carolina Pein3

  • 1Chief Medical Affairs Office, Pfizer Inc, New York City, NY, USA.

Infectious Diseases and Therapy
|April 12, 2024
PubMed
Summary

Ritonavir enhances antiviral drug effectiveness by increasing bioavailability. Despite potential drug-drug interactions, its safety profile is well-established, with manageable risks for healthcare professionals.

Keywords:
COVID-19Concomitant medication managementDrug–drug interactionsHIVNirmatrelvirRitonavir

More Related Videos

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

18.5K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

998

Related Experiment Videos

Last Updated: Jun 28, 2025

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

17.8K
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

18.5K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

998

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Drug Metabolism

Background:

  • Ritonavir is a cytochrome P450 3A4 inhibitor used to boost antiviral drug bioavailability.
  • Its use in HIV and COVID-19 therapies shows a well-tolerated safety profile.
  • Ritonavir's pharmacokinetic enhancement mechanism can lead to drug-drug interactions (DDIs).

Purpose of the Study:

  • To review ritonavir's mechanisms of action as a pharmacokinetic enhancer.
  • To outline strategies for managing concomitant medications and mitigating DDIs.
  • To provide resources for managing adverse events in ritonavir-enhanced therapies.

Main Methods:

  • Literature review of ritonavir's pharmacokinetic properties.
  • Analysis of clinical data regarding DDIs and safety profiles.
  • Synthesis of management approaches for co-medication.

Main Results:

  • Ritonavir effectively increases the bioavailability of co-administered antivirals.
  • Boosting doses of ritonavir are generally well-tolerated.
  • Despite potential DDIs, risks appear manageable by experienced clinicians.

Conclusions:

  • Ritonavir is a valuable pharmacokinetic enhancer in antiviral therapy.
  • Effective co-medication management is crucial for optimizing safety and efficacy.
  • Infectious disease specialists can effectively manage DDIs associated with ritonavir.